A comparison of the EphA2 levels between the healthy group and each stage (I–IV) of cancer patients revealed that the EphA2 levels were significantly higher in cancer patients (healthy individuals vs. Stages I, II, III, IV; p = 0.00298, p = 0.00000734, p = 0.000254, p = 0.000542, respectively) (Figure 2B). This evidence concerns the gene EPHA2 and cancer.